Immunoglobulin D (IgD) myeloma is a rare isotype that comprises 1-2% of multiple myeloma (MM) patients [1-3], which has significantly inferior survival for a median overall survival (OS) between 13 and 21 months [4-6]. Given the lack of large cohort with comprehensive clinical and cytogenetic assessment, knowledge about IgD myeloma is obtained mostly from a limited sample size [7]. Therefore, we carried out a multicenter retrospective study to evaluate the prevalence, clinical features, prognosis, and to develop and validate a prognostic model, including 356 patients with IgD myeloma from 14 centers of Asian Myeloma Network (AMN). Data were collected from China, Korea, and Singapore diagnosed from 2002 to 2019 (Supplementary Table 1). Ethical committee approvals were obtained and study protocol was approved by the Institutional Review Board of each institution. To avoid clinical information leak, and get